4.8 Article

Activation of diverse signalling pathways by oncogenic PIK3CA mutations

Journal

NATURE COMMUNICATIONS
Volume 5, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/ncomms5961

Keywords

-

Funding

  1. Susan G. Komen for the Cure foundation [KG100459]
  2. NIH [U54GM103520, CA43460]
  3. NCI's Clinical Proteomic Tumor Analysis Consortium initiative [U24CA160036]
  4. National Heart, Lung and Blood Institute [HHSN268201000032C]
  5. DOD Era of Hope Scholar Award [BC051652]
  6. NIH SPORE (Specialized Programs of Research Excellence) in Gastrointestinal Cancer Grant) [CA62924]
  7. Virginia and D.K. Ludwig Fund for Cancer Research
  8. Avon Foundation
  9. Breast Cancer Research Foundation
  10. Department of Biotechnology of the Government of India
  11. University Grants Commission, Government of India
  12. Council of Scientific and Industrial Research, Government of India
  13. Majlis Amanah Rakyat (MARA) of Government of Malaysia

Ask authors/readers for more resources

The PIK3CA gene is frequently mutated in human cancers. Here we carry out a SILAC-based quantitative phosphoproteomic analysis using isogenic knockin cell lines containing 'driver' oncogenic mutations of PIK3CA to dissect the signalling mechanisms responsible for oncogenic phenotypes induced by mutant PIK3CA. From 8,075 unique phosphopeptides identified, we observe that aberrant activation of PI3K pathway leads to increased phosphorylation of a surprisingly wide variety of kinases and downstream signalling networks. Here, by integrating phosphoproteomic data with human protein microarray-based AKT1 kinase assays, we discover and validate six novel AKT1 substrates, including cortactin. Through mutagenesis studies, we demonstrate that phosphorylation of cortactin by AKT1 is important for mutant PI3K-enhanced cell migration and invasion. Our study describes a quantitative and global approach for identifying mutation-specific signalling events and for discovering novel signalling molecules as readouts of pathway activation or potential therapeutic targets.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available